Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  2. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
  3. Corresponding author: John G. Keilp, PhD, Box 42, NYSPI, 1051 Riverside Dr, New York, NY 10032 ([email protected]).
  4. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  5. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
  6. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  7. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
  8. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  9. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
  10. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  11. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
  12. Center for Molecular and Behavioral Neuroscience, Rutgers University—Newark, Newark, New Jersey
  13. Palestinian Neuroscience Initiative, Al-Quds University, Jerusalem, Palestine
  14. Center for Molecular and Behavioral Neuroscience, Rutgers University—Newark, Newark, New Jersey
  15. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  16. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
  17. Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
  1. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. PubMed CrossRef
  2. Sinyor M, Williams M, Belo S, et al. Ketamine augmentation for major depressive disorder and suicidal ideation: preliminary experience in an inpatient psychiatry setting. J Affect Disord. 2018;241:103–109. PubMed CrossRef
  3. Ballard ED, Yarrington JS, Farmer CA, et al. Characterizing the course of suicidal ideation response to ketamine. J Affect Disord. 2018;241:86–93. PubMed CrossRef
  4. Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29–45. PubMed CrossRef
  5. Keilp JG, Gorlyn M, Russell M, et al. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013;43(3):539–551. PubMed CrossRef
  6. Keilp JG, Beers SR, Burke AK, et al. Neuropsychological deficits in past suicide attempters with varying levels of depression severity. Psychol Med. 2014;44(14):2965–2974. PubMed CrossRef
  7. Richard-Devantoy S, Berlim MT, Jollant F. A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. Psychol Med. 2014;44(8):1663–1673. PubMed CrossRef
  8. Passie T, Karst M, Wiese B, et al. Effects of different subanesthetic doses of S-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology. 2005;51(4):226–233. PubMed CrossRef
  9. Morgan CJ, Mofeez A, Brandner B, et al. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology. 2004;29(1):208–218. PubMed CrossRef
  10. Honey RA, Turner DC, Honey GD, et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology. 2003;28(11):2037–2044. PubMed CrossRef
  11. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214. PubMed CrossRef
  12. Morgan CJ, Mofeez A, Brandner B, et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology (Berl). 2004;172(3):298–308. PubMed
  13. Morgan CJ, Rossell SL, Pepper F, et al. Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biol Psychiatry. 2006;59(3):265–272. PubMed CrossRef
  14. Hayley A, Green M, Downey L, et al. Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine. Psychopharmacology (Berl). 2018;235(4):1273–1282. PubMed CrossRef
  15. Ke X, Ding Y, Xu K, et al. The profile of cognitive impairments in chronic ketamine users. Psychiatry Res. 2018;266:124–131. PubMed CrossRef
  16. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121–133. PubMed CrossRef
  17. Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, et al. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. 2015;48(2):78–79. PubMed
  18. Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40(5):1084–1090. PubMed CrossRef
  19. Zheng W, Zhou YL, Liu WJ, et al. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord. 2019;246:241–247. PubMed CrossRef
  20. Romeo B, Choucha W, Fossati P, et al. Clinical and biological predictors of ketamine response in treatment-resistant major depression: review [in French]. Encephale. 2017;43(4):354–362. PubMed CrossRef
  21. Keilp JG, Sackeim HA, Mann JJ. Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res. 2005;135(3):191–201. PubMed CrossRef
  22. Wechler D. Wechler Adult Intelligence Scale. 3rd ed. The Psychological Corporation; 1997.
  23. Cornblatt BA, Risch NJ, Faris G, et al. The Continuous Performance Test, identical pairs version (CPT-IP), I: new findings about sustained attention in normal families. Psychiatry Res. 1988;26(2):223–238. PubMed CrossRef
  24. MacLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull. 1991;109(2):163–203. PubMed CrossRef
  25. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24(11):1019–1025. PubMed CrossRef
  26. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. 3rd ed. AJA Associates; 1983.
  27. Gorlyn M, Keilp J, Burke A, et al. Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs bupropion. Psychiatry Res. 2015;225(3):407–412. PubMed CrossRef
  28. Kanto J, Allonen H. Pharmacokinetics and the sedative effect of midazolam. Int J Clin Pharmacol Ther Toxicol. 1983;21(9):460–463. PubMed
  29. Crowe SF, Stranks EK. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2018;33(7):901–911. PubMed CrossRef
  30. Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev. 1985;9(1):87–94. PubMed CrossRef
  31. Keilp JG, Madden SP, Gorlyn M, et al. The lack of meaningful association between depression severity measures and neurocognitive performance. J Affect Disord. 2018;241:164–172. PubMed CrossRef
  32. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. PubMed CrossRef
  33. Ardalan M, Rafati AH, Nyengaard JR, et al. Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus. Br J Pharmacol. 2017;174(6):483–492. PubMed CrossRef
  34. Clarke M, Razmjou S, Prowse N, et al. Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. Neuropharmacology. 2017;112(pt A):210–220. PubMed CrossRef
  35. Dakwar E, Nunes EV, Hart CL, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176(11):923–930. PubMed CrossRef
  36. Dakwar E, Levin F, Hart CL, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–133. PubMed CrossRef
  37. Kaplan S, Berman MG. Directed attention as a common resource for executive functioning and self-regulation. Perspect Psychol Sci. 2010;5(1):43–57. PubMed CrossRef
  38. Hofmann W, Freise M, Roefs A. Three ways to resist temptation: the independent contributions of executive attention, inhibitory control, and affect regulation to the impulse control of eating behavior. J Exp Soc Psychol. 2009;45(2):431–435. CrossRef
  39. Kotabe HP, Hofmann W. On integrating the components of self-control. Perspect Psychol Sci. 2015;10(5):618–638. PubMed CrossRef
  40. Venezia RG, Gorlyn M, Burke AK, et al. The impact of cognitive reserve on neurocognitive performance in major depressive disorder. Psychiatry Res. 2018;270:211–218. PubMed CrossRef
  41. Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606–612. PubMed CrossRef
  42. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. PubMed CrossRef
  43. Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction. 2004;99(11):1450–1461. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe